Satellos Bioscience (MSCLF) Price & Analysis

Compare

26 Followers

MSCLF Stock Chart & Stats

$0.50

$0.00(0.00%)

At close: Jan 08 4:00 PM EST

$0.50

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.38 - $0.94

Previous CloseN/A

Volume2.00K

Average Volume (3M)71.70K

Market Cap

$92.04M

Enterprise Value$68.98M

Total Cash (Recent Filing)$38.22M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.55

Next Earnings

Apr 01, 2026

EPS Estimate

-0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding185,507,160

10 Day Avg. Volume114,158

30 Day Avg. Volume71,701

Financial Highlights & Ratios

PEG Ratio-0.10

Price to Book (P/B)1.40

Price to Sales (P/S)0.00

P/FCF Ratio-3.81

Enterprise Value/Market Cap0.75

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-24.49K

Enterprise Value/Ebitda-2.46

Forecast

1Y Price Target

$0.85

Price Target Upside70.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe company has submitted regulatory applications for a global Phase 2 study to evaluate SAT-3247 in pediatric DMD patients, showing commitment to expanding clinical trials.

Financial PerformanceSatellos reported a lower net loss per share than consensus estimates, indicating better-than-expected financial performance.

Financial StabilitySatellos has cash and cash equivalents of approximately $35M, believed to be sufficient to fund operations into 2027, signaling financial stability.

Bears Say

Revenue ChallengesThe company reported no revenue for 3Q25, highlighting a challenge in generating income at this stage.

Satellos Bioscience News

Satellos Bioscience to Present at December Investor Conferences

An announcement from Satellos Bioscience ( ($TSE:MSCL) ) is now available. Satellos Bioscience Inc. announced its participation in...

1d ago

Buy Rating for Satellos Bioscience Driven by Promising Clinical Developments and Strong Financial Outlook

Analyst Arthur He CFA of H.C. Wainwright maintained a Buy rating on Satellos Bioscience, retaining the price target...

5d ago

Satellos Bioscience Unveils Groundbreaking Research in Duchenne Muscular Dystrophy Treatment

Satellos Bioscience ( ($TSE:MSCL) ) just unveiled an update. Satellos Bioscience announced a significant publication in Nature Communications...

8d ago

Satellos Bioscience Strengthens Leadership and Advances Clinical Trials for DMD Treatment

Satellos Bioscience ( ($TSE:MSCL) ) just unveiled an announcement. Satellos Bioscience announced the appointment of Mark Nawacki to...

12d ago

Satellos Bioscience to Present at November Investor Conferences

Satellos Bioscience ( ($TSE:MSCL) ) just unveiled an announcement. Satellos Bioscience Inc. announced its participation in upcoming investor...

27d ago

Satellos Bioscience’s Long-Term Study on SAT-3247 for DMD: Market Implications

Satellos Bioscience Inc. (($MSCLF)) announced an update on their ongoing clinical study. Satellos Bioscience Inc. is conducting a...

30d ago

MSCLF

Satellos Bioscience Advances Duchenne Treatment with New Study

An update from Satellos Bioscience ( ($TSE:MSCL) ) is now available. Satellos Bioscience has announced the dosing of...

1M ago

Satellos Bioscience Reports Positive Phase 1 Trial Results for Duchenne Muscular Dystrophy Treatment

Satellos Bioscience ( ($TSE:MSCL) ) has issued an update. Satellos Bioscience announced promising new data from a Phase...

2M ago

Satellos Bioscience announces data on tolerability, initial efficacy of SAT-3247

Satellos Bioscience (MSCLF) announced new data further demonstrating tolerability and initial efficacy of SAT-3247 in adults with Duchenne...

2M ago

Satellos Bioscience to Present Key Findings on Duchenne Treatment at World Muscle Society Congress

Satellos Bioscience ( ($TSE:MSCL) ) has issued an announcement. Satellos Bioscience announced its participation in the 30th Annual...

2M ago

Satellos Bioscience Advances Phase 2 Trial for Duchenne Muscular Dystrophy Treatment

An update from Satellos Bioscience ( ($TSE:MSCL) ) is now available. Satellos Bioscience has submitted an Investigational New...

2M ago

Satellos Bioscience price target raised to C$1.25 from C$1 at Canaccord

Canaccord raised the firm’s price target on Satellos Bioscience (MSCLF) to C$1.25 from C$1 and keeps a Speculative...

11M ago

Satellos Bioscience initiated with a Speculative Buy at Canaccord

Canaccord analyst Tania Armstrong-Whitworth initiated coverage of Satellos Bioscience with a Speculative Buy rating and C$1 price target....

1y ago

Satellos Bioscience submits clinical research proposal to HREC for SAT-3247

Satellos Bioscience announced submission of a clinical research proposal to a Human Research Ethics Committee, or HREC, in...

1y ago

MSCLF FAQ

What was Satellos Bioscience Inc.’s price range in the past 12 months?

Satellos Bioscience Inc. lowest stock price was $0.38 and its highest was $0.94 in the past 12 months.

What is Satellos Bioscience Inc.’s market cap?

Satellos Bioscience Inc.’s market cap is $92.04M.

When is Satellos Bioscience Inc.’s upcoming earnings report date?

Satellos Bioscience Inc.’s upcoming earnings report date is Apr 01, 2026 which is in 126 days.

How were Satellos Bioscience Inc.’s earnings last quarter?

Satellos Bioscience Inc. released its earnings results on Nov 13, 2025. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of -$0.027 by -$0.003.

Is Satellos Bioscience Inc. overvalued?

According to Wall Street analysts Satellos Bioscience Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Satellos Bioscience Inc. pay dividends?

Satellos Bioscience Inc. does not currently pay dividends.

What is Satellos Bioscience Inc.’s EPS estimate?

Satellos Bioscience Inc.’s EPS estimate is -0.03.

How many shares outstanding does Satellos Bioscience Inc. have?

Satellos Bioscience Inc. has 185,507,160 shares outstanding.

What happened to Satellos Bioscience Inc.’s price movement after its last earnings report?

Satellos Bioscience Inc. reported an EPS of -$0.03 in its last earnings report, missing expectations of -$0.027. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Satellos Bioscience Inc.?

Currently, no hedge funds are holding shares in MSCLF

Satellos Bioscience Stock Smart Score

Underperform

Fundamentals

Return on Equity

-89.10%

Trailing 12-Months

Asset Growth

109.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Satellos Bioscience Inc.

Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Satellos Bioscience (MSCLF) Earnings & Revenues

Historic Earnings Reports

MSCLF Stock 12 Month Forecast

Average Price Target

$0.85

▲(70.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","-1":"-$1","-0.5":"-$0.5","0.5":"$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.85</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.5638461538461539,0.5876923076923077,0.6115384615384616,0.6353846153846154,0.6592307692307693,0.6830769230769231,0.706923076923077,0.7307692307692308,0.7546153846153847,0.7784615384615385,0.8023076923076924,0.8261538461538461,{"y":0.85,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.5638461538461539,0.5876923076923077,0.6115384615384616,0.6353846153846154,0.6592307692307693,0.6830769230769231,0.706923076923077,0.7307692307692308,0.7546153846153847,0.7784615384615385,0.8023076923076924,0.8261538461538461,{"y":0.85,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.5638461538461539,0.5876923076923077,0.6115384615384616,0.6353846153846154,0.6592307692307693,0.6830769230769231,0.706923076923077,0.7307692307692308,0.7546153846153847,0.7784615384615385,0.8023076923076924,0.8261538461538461,{"y":0.85,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.41,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.59,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.51,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.46,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.39,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >